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HF, including hospital readmissions and surviv‑
al. The second aim was to analyze the insurer’s 
costs of treatment in DCHFUs.
Methods A day ‑care HF unit was founded at the 
3rd Department of Cardiology, Silesian Centre for 
Heart Diseases in Zabrze, Poland, a tertiary car‑
diovascular hospital. The unit was equipped with 
3 comfortable chairs with vital function monitors 
and infusion pumps. Visits were scheduled for 
each patient individually, depending on the cur‑
rent clinical status, and were conducted by a dedi‑
cated HF nurse and physician. In the stable phase 
of HF, patients had 1 to 3 visits per month, and in 
case of clinical problems, the visits were sched‑
uled even 2 to 3 times a week. During each visit, 
physical examination was performed with mea‑
surement of body weight, blood pressure and sat‑
uration, electrocardiogram, and laboratory tests. 
Additional tests, including chest X ‑ray, transtho‑
racic echocardiography, interrogation of implant‑
able cardioverter defibrillator (ICD) or cardiac re‑
synchronization therapy with defibrillator (CRT‑
‑D) device were also available. Drugs, including 
intravenous diuretic, dobutamine, and potassium 
supplementation were also administered when 
needed. Patients had the possibility of telephone 
contact with the unit and those with implanted 
ICD/CRT ‑D were monitored remotely.
Only optimally decongested patients with 
class II‑IV HF according to the New York Heart 
Association functional classification with all 
possible reparative procedures performed (re‑
vascularization, correction of valvular disease, 
ablation), implanted ICD/CRT ‑D if applicable, 
Introduction Heart failure (HF) is a major 
health and financial burden worldwide. Despite 
the advances in cardiology, the prevalence of HF 
is increasing and the outcomes remain poor. In 
90‑day follow‑up after HF hospitalization, hos‑
pital readmission and readmission rates are 21% 
to 47% and 8% to 16%, respectively, and are 
supposed to be higher in patients with refrac‑
tory HF.1,2 Although the “transition phase” is 
the most vulnerable period after hospital dis‑
charge, 75% of readmissions in this time may 
be preventable.3 The European Society of Car‑
diology guidelines recommended for the first 
time that patients with HF should be enrolled 
in a multidisciplinary care management pro‑
gram to reduce not only the risk of HF hospital‑
ization but also mortality (Class I, level of rec‑
ommendation A).4 The first well described day‑
‑care HF unit (DCHFU) with multidisciplinary 
management program was introduced at the She‑
ba Medical Centre, Israel. The safety of the day‑
‑care service among patients with advanced HF 
was confirmed with lower than expected rates 
of hospital readmission and mortality.5 DCHFUs 
were also introduced as an element of the coor‑
dinated heart failure care program (Komplek‑
sowa Opieka w Niewydolności Serca) by the Pol‑
ish Ministry of Health in 2018.6 We hypothe‑
sized that the individualized and comprehen‑
sive treatment in a DCHFU aimed at maintaining 
the effect of the hospital treatment may improve 
the prognosis also among those with recurrent 
rehospitalizations. The purpose of the study was 
to determine the effects of treatment in a DCF‑



















S H O R T  C O M M U N I C A T I O N
Improved prognosis in patients with  
recurrent hospitalizations for heart  
failure after day‑care management
Mariusz Gąsior1, Jacek T. Niedziela1, Jacek Sikora1, Elżbieta Gadula ‑Gacek1, Anna Kurek1, 
Aneta Ociessa1, Krystyna Czapla1, Beata Szeliga ‑Dańko1, Jolanta Nowak1, Piotr Rozentryt1,2
1  3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
2  Department of Toxicology and Health Protection, School of Public Health in Bytom, Medical University of Silesia in Katowice, Bytom, Poland
KARDIOLOGIA POLSKA 2019; 77 (10)976
and with at least 2 unplanned hospitalizations 
for HF during preceding 6 months were includ‑
ed in the study during HF hospitalization.
At baseline, the medical history, clinical and 
biochemical parameters, as well as data on drugs 
and procedures were recorded and the estimated 
survival time and probability of 12‑month sur‑
vival were calculated using the Seattle Heart Fail‑
ure Model (SHFM) Calculator version 2.10000.7
The all ‑cause death, hospitalizations for acute 
HF, and heart transplantation (HTx) or left ven‑
tricular assist device implantations were analyzed.
The treatment costs to the Polish Nation‑
al Health Fund (Narodowy Fundusz Zdrow‑
ia [NFZ]), the only Polish public insurer, for 
the 6‑month period before inclusion were cal‑
culated as the cost of 2 hospitalizations due to 
HF according to the NFZ estimation. The overall 
costs to the NFZ during the 6‑month treatment 
in DCHFUs were calculated as the summary costs 
of all visits in DHCFUs (accounted for outpa‑
tient clinic) and all unplanned hospitalizations 
for acute HF according to the NFZ estimation.
Statistical analysis Continuous variables with 
normal distribution were presented as means 
(SD) and those with other than normal distri‑
bution as medians (IQR). Categorical variables 
were presented as percentages.
The  investigation conforms with the princi‑
ples outlined in the  Declaration of Helsin‑
ki. The study was approved by the Bioethics 
Committee of the Medical University of Silesia 
(KNW/0022/KB1/150/15/16).
Results and discussion A total of 83 patients 
were enrolled in the study. During the medi‑
an (IQR) follow ‑up of 268 (623) days, 2426 vis‑
its were recorded. The baseline characteristics 
and main results are presented in TABle 1. There 
were no serious adverse events during the visits 
in the DCHFU. During the 6‑month treatment 
in the DCHFU, 3.3% of patients had 2 hospital 
readmissions due to HF decompensation com‑
pared with at least 2 hospitalizations for acute 
HF in all participants in the same period before 
inclusion to the DCHFU. Among patients who 
completed a 12‑month follow ‑up, the median 
(IQR) of estimated 12‑month survival rate ac‑
cording to the SHFM was 55.8% (54.0%), while 
the observed 12‑month survival reached 76.1%. 
The average treatment costs to the NFZ during 
the 6‑month period before inclusion to the DCH‑
FU were 2.9‑fold higher than during the first 6 
months of treatment in the DCHFU (TABle 1).
Patients included in the study were young‑
er and had higher prevalence of comorbid‑
ities than the average Silesian population of 
HF patients.8 Comparing with HF patients in 
COMMIT ‑HF (Contemporary Modalities in 
Treatment of Heart Failure) registry, the age was 
similar, but the prevalence of comorbidities and 
Table 1 Characteristics at baseline and during the treatment at a day ‑care heart 
failure unit (continued on the next page)
Parameter Value
Number of visits 2426
Number of patients 83
Treatment time in DCHFU / follow ‑up, d, median (IQR) 268 (623)
Visits per patient per month, n, mean (SD) 3.7 (2.7)
Age, y, mean (SD) 62.2 (10.7)
Female sex, % 12.1
BMI, kg/m2, median (IQR) 26.5 (6.0)
Ischemic etiology, % 62.7
History of arterial hypertension, % 65
History of atrial fibrillation, % 71
History of VT/VF, % 33
History of stroke, % 15
History of diabetes mellitus, % 43
History of chronic kidney disease, % 59




LVEF, %, median (IQR) 18.0 (7.5)
LVEDD, mm, median (IQR) 70.0 (13.0)
LVEDV, ml, mean (SD) 233 (92)
NT ‑proBNP, pg/ml, median (IQR) 3656 (4225)
Distance from home to DCHFU, km, median (IQR) 15.7 (19.4)
ICD/CRT ‑D, % 91
Remote monitoring of ICD/CRT ‑D, % 82
Loop diuretic, % 100
β ‑Blocker, % 97
β ‑Blocker, % of recommended dose 55
ACEI/ARB/ARNI, % 64
ACEI/ARB/ARNI, % of recommended dose 35
MRA, % 94





Potassium supplementation, % 73
OAC/NOAC, % 79
Visits with loop diuretic administration IV, % 60
Visits with potassium supplementation, % 21
Visits with ICD/CRT ‑D interrogation, % 5.4
Visits with TTE, % 2.8
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self ‑management, drug compliance, and possibil‑
ity of visiting the DCHFU on their own. Patients 
with dementia and / or frailty should be proba‑
bly referred for palliative treatment in a nursing 
home or hospice. Patients with mild symptoms of 
HF or those with low risk of HF hospitalization 
(without previous HF hospitalizations), should 
be treated in out patient clinics.
The study has some limitations. There was no 
control group or possibility of data collection in 
similar population without treatment in the DCH‑
FU. Thus, the results should be interpreted with 
caution as the only comparison may be done with 
estimated data or data available in other publica‑
tions. However, in readmission and cost analyses, 
the control group was composed of the same pa‑
tients treated in the same period before inclusion 
to the DCHFU. The overall costs of the DCHFU 
for the hospital are difficult to assess and were 
not analyzed in the current study. In our opinion, 
randomized trials may be difficult to conduct, due 
to concerns regarding heterogeneity of patients 
characteristics, limited number of patients, and 
ethical aspects of depriving patients of potential‑
ly beneficial treatment at a day ‑care unit.
Day ‑care HF units seem to be an efficient op‑
tion for patients with recurrent hospitalizations 
due to HF, which may allow to improve outcomes 
and reduce insurer’s costs.
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concentrations of N‑terminal pro‑B‑type natri‑
uretic peptide were higher, while left ventric‑
ular ejection fraction was considerably lower.9
We showed that simple but individualized care 
in the day ‑care unit may reduce the rate of hospital 
readmissions for acute HF and insurer costs as well 
as improve the 12‑month survival comparing with 
the SHFM estimations. Our findings suggest that 
the DCHFU may be designed as a bridge therapy 
for patients qualified for HTx (36% of patients) or 
the observation list (24%), but also as a destination 
therapy for patients without the possibility of im‑
planting left ventricular assist device or HTx (40%).
According to our experience, the day ‑care 
treatment may be beneficial only to decongest‑
ed patients who were treated optimally and had 
all corrective procedures performed. Patients 
with acute HF should be referred immediately to 
the hospital emergency department. Such an ap‑
proach, also recommended by the European Soci‑
ety of Cardiology guidelines, should be similar to 
acute coronary syndromes management accord‑
ing to the “time is organs” principle. Another im‑
portant issue is patient cooperation, including 
Table 1 Characteristics at baseline and during the treatment at a day ‑care heart 
failure unit (continued from the previous page)
Parameter Value
Patients who underwent LVAD implantation or HTx, % 33.7
At least 1 hospital readmission due to acute HF during the whole 
follow ‑upa, %
42.2
At least 1 hospital readmission due to acute HF during 6‑month follow‑
‑upa, %
27.7
At least 2 hospital readmissions due to acute HF during the whole 
follow ‑upa, %
13.3
At least 2 hospital readmissions due to acute HF during 6‑month 
follow ‑upa, %
3.6
The probability of 12‑month survival estimated by SHFM in time of 
inclusion to DCHFU, %, median (IQR)b
55.8 (54.0)
The estimated survival time according to SHFM, y, median (IQR)b 1.65 (4.4)
Survival in 12‑month follow ‑upb, % 76.1
The insurer costs of 6‑month treatment before inclusion to DCHFU per 
patient, PLNc
6908
The insurer costs of 6‑month treatment after inclusion to DCHFU per 
patient, PLNc
2385
a Hospitalizations related to the heart transplantation were not included.
b Analysis for patients who completed the 12‑month follow ‑up in the DCHFU (n = 46)
c 1 PLN = 0.23 EUR
Abbreviations: ACEI, angiotensin ‑converting enzyme inhibitors; ARB, angiotensin II receptor 
blockers; ARNI, angiotensin receptor ‑neprilysin inhibitor; BMI, body mass index; CRT ‑D, cardiac 
resynchronization therapy defibrillator; DCHFU, day ‑care heart failure unit; HF, heart failure; HTx, 
heart transplantation, ICD, implantable cardioverter defibrillator; IQR, inter quartile range; IV, 
intravenous; LVAD, left ventricular assist device; LVEDD, left ventricular end diastolic diameter; LVEDV, 
left ventricular end diastolic volume; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid 
receptor antagonist; NOAC, non ‑vitamin K antagonist oral anticoagulants; NT ‑proBNP, N‑terminal 
pro‑B‑type natriuretic peptide; NYHA, New York Heart Association functional classification; OAC, oral 
anticoagulation therapy; SHFM, Seattle Heart Failure Model; TTE, transthoracic echocardiography; 
VF, ventricular fibrillation; VT, ventricular tachycardia
